A community-based survey of varicella-zoster virus-specific immune responses in the elderly

Journal of Clinical Virology

Volumn 55, Issue 1, 2012, Pages 46-50

  Tang, Huamin ^a,b   Moriishi, Eiko ^b   Okamoto, Shigefumi ^b   Okuno, Yoshinobu ^c   Iso, Hiroyasu ^d   Asada, Hideo ^e   Yamanishi, Koichi ^b   Mori, Yasuko ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c Osaka University   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell mediated immunity; Humoral immunity; Interferon ELISPOT assay; Skin test; Varicella zoster virus

Indexed keywords

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; ELDERLY CARE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL PROCEDURES; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN TEST; VARICELLA ZOSTER VIRUS;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION TESTS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA RELEASE TESTS; JAPAN; MALE; MIDDLE AGED; SKIN TESTS;

EID: 84865175979     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.06.008     Document Type: Article

References (19)

1. Arvin A.M. Varicella-zoster virus. Clin Microbiol Rev 1996, 9:361-381.
2. Berger R., Florent G., Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981, 32:24-27.
3. Buchbinder S.P., Katz M.H., Hessol N.A., Liu J.Y., O'Malley P.M., Underwood R., et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992, 166:1153-1156.
4. McDonald J.R., Zeringue A.L., Caplan L., Ranganathan P., Xian H., Burroughs T.E., et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009, 48:1364-1371.
5. Okamoto S., Hata A., Sadaoka K., Yamanishi K., Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis 2009, 200:1606-1610.
6. Levin M.J., Murray M., Rotbart H.A., Zerbe G.O., White C.J., Hayward A.R. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992, 166:253-259.
7. Levin M.J., Smith J.G., Kaufhold R.M., Barber D., Hayward A.R., Chan C.Y., et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003, 188:1336-1344.
8. Miller A.E. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980, 30:582-587.
9. Sadaoka K., Okamoto S., Gomi Y., Tanimoto T., Ishikawa T., Yoshikawa T., et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 2008, 198:1327-1333.
10. Hata A., Asanuma H., Rinki M., Sharp M., Wong R.M., Blume K., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002, 347:26-34.
11. Toyama N., Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009, 81:2053-2058.
12. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
13. Takao Y., Miyazaki Y., Onishi F., Kumihashi H., Gomi Y., Ishikawa T., et al. The Shozu Herpes Zoster (SHEZ) Study: rationale, design, and description of a prospective cohort study. J Epidemiol 2012, 22:167-174.
14. Takahashi M., Okada S., Miyagawa H., Amo K., Yoshikawa K., Asada H., et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003, 21:3845-3853.
15. Shiraki K., Okuno T., Yamanishi K., Takahashi M. Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV). J Gen Virol 1982, 61(Pt 2):255-269.
16. Levin M.J., Oxman M.N., Zhang J.H., Johnson G.R., Stanley H., Hayward A.R., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008, 197:825-835.
17. Breuer J., Schmid D.S., Gershon A.A. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis 2008, 197(Suppl. 2):S147-S151.
18. Smith J.G., Liu X., Kaufhold R.M., Clair J., Caulfield M.J. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001, 8:871-879.
19. Kamiya H., Ihara T., Hattori A., Iwasa T., Sakurai M., Izawa T., et al. Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J Infect Dis 1977, 136:784-788.